GLP-1s and the liver: what the MASH approval actually covers

TL;DR

• August 2025, accelerated approval - the FDA cleared semaglutide for adults with non-cirrhotic MASH and F2–F3 fibrosis, the first GLP-1 receptor agonist with that indication.
• The indication is narrow by design - it excludes cirrhosis (F4), excludes F0–F1, and does not cover "fatty liver" as a general condition.
• ESSENCE Part 1, 72 weeks, 800 adults: MASH resolution 62.9% vs 34.3% on placebo; fibrosis improvement 36.8% vs 22.4%.
• These are histological surrogate endpoints, not cirrhosis, transplant or death - the trial runs 240 weeks and Part 2 is expected in 2029.
• Fibrosis stage, not liver fat, is the strongest predictor of mortality, which is why the approval is written around F2–F3.
• Being on a GLP-1 for weight is not being treated for liver disease; tirzepatide and retatrutide remain investigational for MASH.

---

What was approved, precisely

The precision matters here more than in almost any other GLP-1 story, because the gap between what was approved and what people assume was approved is wide.

In August 2025, the FDA granted accelerated approval to once-weekly semaglutide, at its weight-management strength, for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis - stages F2 to F3. It is the first GLP-1 receptor agonist to become available for this indication.

Four qualifiers are doing real work in that sentence, and each of them narrows it:

• Non-cirrhotic. People with cirrhosis (F4) were not studied and are not covered.
• MASH, not MASLD. Steatohepatitis, not simple fatty liver.
• F2 to F3. A specific fibrosis band, not the whole spectrum.
• Accelerated approval. A conditional regulatory pathway, not a standard one.

The approval attaches to one specific labelled strength, and we deliberately do not print the figure here. A number lifted off a page has a way of becoming a plan, and dosing, eligibility and monitoring for a liver indication are entirely a prescribing clinician's territory. The strength is on the label, where the person writing the prescription will read it.

The American Association for the Study of Liver Diseases (AASLD) updated its Practice Guidance in November 2025 to address semaglutide in MASH, which is the ordinary sequence: a regulator approves, and the specialty society then works out how the drug fits into the way liver disease is actually staged and managed in clinic.

What MASH is and why the liver became a GLP-1 target

The metabolic chain

MASLD - metabolic dysfunction-associated steatotic liver disease - is not one condition but a spectrum, and the stages are not interchangeable.

It begins with steatosis: fat accumulating inside liver cells. On its own, this is extremely common and, for many people, relatively inert. When fat accumulation is accompanied by inflammation and hepatocyte injury, the picture becomes steatohepatitis (MASH) - the liver is not just storing fat, it is being damaged. Sustained injury drives a repair response, and that repair response deposits scar tissue: fibrosis, staged from F0 (none) through F1, F2 and F3 to F4 (cirrhosis), where architecture is distorted and function is threatened.

The reason a metabolic drug ended up with a liver indication is that this chain is metabolic from the first link. Hepatic fat accumulation is tightly coupled to insulin resistance, visceral adiposity and the broader dysregulation that also produces type 2 diabetes and cardiovascular risk. The liver in MASH is not an isolated organ with its own disease; it is one of the places where a systemic metabolic problem becomes visible and, eventually, structural.

Why fibrosis stage is the variable that matters

This is the single most useful thing a non-specialist can take from the topic.

Fibrosis stage - not the amount of fat - is the strongest predictor of liver-related and overall mortality in this disease. Two people can have similar-looking fat on imaging and radically different prognoses depending on how much scarring has accumulated. Fat is the mechanism; scar is the outcome.

That is precisely why the indication is written around F2–F3 rather than around "fatty liver". Regulators approved a treatment for the group in whom the disease is demonstrably progressing towards the outcomes that matter, in whom there is still substantial reversible disease, and in whom the trial actually measured something. It is a deliberately targeted approval, not a general licence for hepatic steatosis.

What ESSENCE showed at 72 weeks

The approval rested on interim data from Part 1 of the phase 3 ESSENCE trial, which enrolled 800 adults with biopsy-confirmed MASH and F2–F3 fibrosis. The full trial runs 240 weeks, and Part 2 results are expected in 2029.

At 72 weeks, on the trial's two co-primary histological endpoints:

A few things are worth reading carefully in that table.

This is randomised-trial evidence - the strongest tier available for a therapeutic question, because randomisation makes the comparison group structurally similar to the treated group. The differences are not observational associations.

The placebo arm moved substantially too. A third of placebo participants achieved MASH resolution and more than a fifth improved a fibrosis stage. Trial participation involves lifestyle attention, structured follow-up and repeated contact, and MASH is a condition that responds to those things. The clinically meaningful quantity is the difference between arms, not the treated-arm number in isolation.

These are histological endpoints, not clinical outcomes. MASH resolution and fibrosis stage are surrogate markers - well-motivated ones, strongly linked to prognosis, and accepted by regulators for exactly that reason. But they are not the same as demonstrated reductions in cirrhosis, liver failure, transplant or death. That distinction is the whole reason the approval took the form it did.

And this is Part 1 of a longer trial. Seventy-two weeks of histology in 800 people is a substantial dataset. It is not the 240-week picture, and the durability question is genuinely open until it reports.

What accelerated approval means here

Accelerated approval is a specific regulatory pathway, and it means something narrower than "approved".

Under it, a drug can be authorised for a serious condition on the basis of an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit - here, liver histology - rather than on demonstrated clinical benefit itself. In exchange, confirmatory evidence is still owed. The obligation is real and outstanding: the ESSENCE trial continues to 240 weeks precisely to supply it, with Part 2 expected in 2029.

The honest framing for a reader is therefore: this is a real approval, granted on real randomised evidence, on a conditional basis, with the confirming outcome data still to come. It is not a provisional gesture, and it is not a finished case. If you want the fuller regulatory mechanics - what the pathway requires, what happens if confirmatory trials fail, and how it differs from standard approval - see our explainer on what accelerated approval actually means.

One phrase to retire while reading coverage of this: "reviewed by an advisory committee" is not "approved", and "approved on an accelerated basis" is not "proven to prevent liver failure".

Who this indication is not for

Approvals define populations, and the population here excludes far more people than it includes.

People with cirrhosis (F4). Explicitly excluded. The trial studied non-cirrhotic disease, and the label follows the trial. Decompensated and compensated cirrhosis raise entirely different clinical questions, and this approval answers none of them.

People at F0–F1. The studied population was F2–F3. The approval says nothing about earlier fibrosis - not that treatment would fail there, but that it was not tested there. Absence of evidence is the correct description, and it is not evidence of absence in either direction.

People with steatosis but no steatohepatitis. Fat without inflammation and injury is not the indication.

People with no liver diagnosis at all. This is the one that most needs saying plainly: being on a GLP-1 for weight is not the same as being treated for liver disease. A weight-management prescription is not a MASH prescription. The indication requires a diagnosis, staging, and a clinical decision - none of which happen incidentally.

It is also worth stating that this approval is evidence about semaglutide and about semaglutide only. Tirzepatide has been studied in MASH; it is investigational for this indication and no approval exists for it in MASH. Retatrutide, whose glucagon-receptor component carries a mechanistic rationale for reducing hepatic lipid, is investigational, is not FDA-approved for any indication, and is certainly investigational for this indication. Class-level reasoning is not evidence. A result for one molecule at one strength in one trial population does not transfer.

Weight loss versus a direct hepatic effect - an open question

This is the most interesting unresolved question in the topic, and it should not be resolved on this page in either direction.

MASH is tightly coupled to adiposity and insulin resistance. Substantial weight loss, from any cause, improves liver histology - this is well established, and it is why lifestyle intervention and bariatric surgery both produce histological improvement. Semaglutide produces substantial weight loss. So a large part of the ESSENCE effect is plausibly the weight loss doing what weight loss does.

Against that, there are mechanistic reasons to think GLP-1 receptor agonism might do something to the liver beyond mass reduction - improved insulin sensitivity, reduced lipotoxic substrate delivery, dampened inflammatory signalling. These are mechanistic hypotheses, and mechanistic plausibility is the weakest evidence tier there is.

ESSENCE Part 1 does not settle it. The trial was designed to answer whether semaglutide improves histology versus placebo, and it answered that. It was not designed as a weight-matched comparison, which is what would be required to isolate a hepatic effect independent of weight loss.

Why does it matter for a reader? Because the answer changes what you would conclude about other routes to the same weight loss, and about people who lose little weight on treatment. If the effect is largely weight-mediated, the achievement is a reliable, tolerable way of producing weight loss at scale - which is not a small thing. If there is an additional direct hepatic effect, the drug is doing something a diet cannot. We do not currently know which, and anyone stating it confidently is ahead of the data.

What this changes for someone already on a GLP-1 for weight

In practice: a conversation with their prescriber, and nothing else.

Not a self-directed change of any kind. Not an assumption that a weight-management prescription is quietly also liver treatment. Not a reason to seek a higher strength, and not a reason to relax about a liver result that was flagged in the past.

What the approval reasonably does is make the liver a legitimate agenda item for that conversation. If you have had abnormal liver enzymes, a fatty liver noted on an ultrasound, type 2 diabetes, or the metabolic risk profile that travels with MASH, it is entirely reasonable to ask your clinician whether your liver has been assessed and staged, and what that would involve. Whether anything follows from that is their call, made on your individual picture.

Broader monitoring context sits alongside this - our notes on GLP-1s and cancer risk, GLP-1s and bone density and GLP-1s and gallbladder risk cover the other organ-system questions that come up during sustained treatment, and the semaglutide overview covers the molecule itself.

Frequently asked questions

Does this apply to tirzepatide? No. The approval is for once-weekly semaglutide at a single labelled strength, on the basis of the ESSENCE trial. Tirzepatide has been studied in MASH but remains investigational for this indication, with no FDA approval in MASH. The same applies to retatrutide, which is investigational and not FDA-approved for any indication. Results from one molecule do not transfer to another, even within a related class - that is a rule of evidence, not a technicality.

Do I need a biopsy? The ESSENCE trial used biopsy-confirmed MASH and biopsy-staged fibrosis, which is why the evidence is as specific as it is. In routine practice, non-invasive tests - elastography and fibrosis scoring systems built from blood markers - are increasingly used to identify who needs further assessment, and biopsy is not automatic. But diagnosis and staging are a clinician's job, using the tools appropriate to your situation. There is no testing protocol on this page and no self-assessment route, because interpreting these results depends on context that a reader cannot supply for themselves.

Is it covered by insurance? That varies by country, insurer and plan, and it is not something this article can answer. What is worth knowing is that coverage for a MASH indication generally depends on a documented diagnosis and fibrosis stage - meaning the assessment usually has to come first regardless. Your prescriber and insurer are the only reliable sources here.

Does it reverse cirrhosis? No claim of that kind is supported. Cirrhosis (F4) was excluded from the trial that supported the approval, and the indication is explicitly for non-cirrhotic disease. Nothing in ESSENCE Part 1 speaks to cirrhosis. Fibrosis improvement of at least one stage was seen in a minority of treated participants at F2–F3, which is a meaningful histological result in that population and is not a statement about reversing established cirrhosis.

Related reading

• Semaglutide: the molecule, the evidence and the indications
• What accelerated approval actually means
• GLP-1s and cancer risk: reading the signal honestly
• GLP-1s and bone density: the question behind the muscle-loss conversation
• GLP-1s and gallbladder risk: two mechanisms, one association

Part of The Complete Guide to GLP-1s.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore semaglutide.

---

This article is educational and does not constitute medical advice. Semaglutide is a prescription medicine and its use in MASH requires diagnosis, staging and supervision by a qualified physician. No dosing guidance, titration schedules or protocols appear above; the labelled strength is stated only as a regulatory fact. Tirzepatide and retatrutide are investigational for this indication and are not FDA-approved for MASH. Claims for the Malaysian market are subject to MAB requirements.

References

• U.S. Food and Drug Administration (August 2025) - Accelerated approval of once-weekly semaglutide (weight-management strength) for adults with non-cirrhotic MASH with moderate-to-advanced fibrosis (F2–F3).
• ESSENCE phase 3 trial, Part 1 interim analysis at 72 weeks - MASH resolution without worsening of fibrosis and fibrosis improvement without worsening of MASH; 800 adults with biopsy-confirmed MASH and F2–F3 fibrosis; full trial duration 240 weeks, Part 2 expected 2029.
• American Association for the Study of Liver Diseases (November 2025) - Practice Guidance update addressing semaglutide in MASH.
• General references on the MASLD/MASH spectrum and the prognostic weight of fibrosis stage for liver-related and all-cause mortality.
• General references on the FDA accelerated approval pathway and confirmatory evidence obligations.